Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)

Launched by WESTERN GALILEE HOSPITAL-NAHARIYA · Feb 10, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring how certain new medications for lowering blood sugar levels can help patients with diabetes and kidney disease. The researchers want to see if these medications, known as SGLT2 inhibitors (like Forxiga and Jardiance) and GLP-1 receptor agonists (like Ozempic), can reduce a process called NETosis. NETosis is when certain immune cells form traps that can worsen complications like heart disease and kidney damage in diabetic patients. The trial also looks at how immunosuppressive therapies can affect NETosis in patients with specific kidney diseases, aiming to find better ways to manage inflammation and improve health outcomes.

To participate in this trial, you need to be at least 18 years old and have diabetes or chronic kidney disease. Specifically, they are looking for diabetic patients who have not used SGLT2 inhibitors or GLP-1 receptor agonists before, as well as patients with immune-related kidney diseases like ANCA-associated vasculitis. During the study, participants will receive treatment and regular check-ups to monitor their health. It’s important to know that individuals with certain acute infections or blood diseases, or those who test positive for HIV or Hepatitis B/C, cannot take part in this study. Overall, this research hopes to find new ways to improve the health of people with diabetes and kidney disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • DM therapy study: - Diabetic patients aged 18 years or older (men and women).
• • Patients who have not previously received SGLT2 inhibitors or GLP-1 receptor agonists.
• • -Chronic kidney disease (CKD) patients :50 CKD patients with various etiologies.
• • Focus:
• • This part of the study will specifically evaluate immune-mediated kidney disease, such as ANCA-associated vasculitis, and the effects of immunosuppressive therapy on NETosis.
• • Exclusion Criteria:
• • Patients with acute infections, hematologic or oncologic diseases, or positive for HIV or Hepatitis B/C